Table 1.
Comparison of blood lipid by BIC/FTC/TAF and 3TC+EFV+TDF groups of treatment-naïve adult male patients with HIV/AIDS at different time points.
| Characteristics | Baseline | 4 weeks | 12 weeks | 24 weeks | 48 weeks | ADF‡ | P-value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | D* | Z† | P-value | Mean ± SD | D* | Z† | P-value | Mean ± SD | D* | Z† | P-value | Mean ± SD | D* | Z† | P-value | |||
| TG (mmol/L) | |||||||||||||||||||
| BIC/FTC/TAF | 1.61 ± 1.01 | 1.80 ± 1.18 | 0.08 | 144,889 | 0.019 | 1.78 ± 1.21 | 0.10 | 142,280 | 0.032 | 2.13 ± 2.33 | 0.15 | 70,119 | 0.022 | 1.78 ± 1.41 | 0.06 | 24,577 | 0.719 | –20.345 | <0.001 |
| 3TC+EFV+TDF | 1.41 ± 1.13 | 1.58 ± 1.13 | 0.13 | 106,254 | <0.001 | 1.54 ± 0.94 | 0.15 | 81,877 | 0.013 | 1.58 ± 1.25 | 0.03 | 36,207 | 0.134 | 1.57 ± 1.15 | 0.13 | 21,710 | 0.219 | –18.816 | <0.001 |
| TC (mmol/L) | |||||||||||||||||||
| BIC/FTC/TAF | 4.43 ± 0.90 | 4.61 ± 0.90 | 0.23 | 148,427 | 0.002 | 4.63 ± 0.86 | 0.26 | 150,865 | <0.001 | 4.75 ± 1.01 | 0.30 | 75,425 | <0.001 | 4.59 ± 0.78 | 0.20 | 26,926 | 0.062 | –20.235 | <0.001 |
| 3TC+EFV+TDF | 4.31 ± 0.82 | 4.22 ± 0.78 | –0.08 | 87,870 | 0.101 | 4.25 ± 0.80 | –0.06 | 70,077 | 0.187 | 4.36 ± 0.80 | 0.01 | 32,334 | 0.698 | 4.42 ± 0.73 | 0.12 | 21,910 | 0.165 | –19.817 | <0.001 |
| HDL-C (mmol/L) | |||||||||||||||||||
| BIC/FTC/TAF | 1.05 ± 0.41 | 1.10 ± 0.32 | 0.09 | 154,837 | <0.001 | 1.13 ± 0.36 | 0.10 | 158,488 | <0.001 | 1.14 ± 0.38 | 0.09 | 76,694 | <0.001 | 1.16 ± 0.29 | 0.14 | 30,793 | <0.001 | –21.078 | <0.001 |
| 3TC+EFV+TDF | 1.01 ± 0.27 | 0.99 ± 0.25 | 0 | 90,913 | 0.413 | 1.04 ± 0.25 | 0.03 | 80,339 | 0.046 | 1.06 ± 0.26 | 0.08 | 36,322 | 0.006 | 1.13 ± 0.26 | 0.15 | 25,964 | <0.001 | –19.380 | <0.001 |
| LDL-C (mmol/L) | |||||||||||||||||||
| BIC/FTC/TAF | 2.72 ± 0.76 | 2.81 ± 0.76 | 0.08 | 143,271 | 0.045 | 2.86 ± 0.77 | 0.15 | 147,839 | <0.001 | 2.85 ± 0.81 | 0.10 | 69,384 | 0.042 | 2.78 ± 0.64 | 0.09 | 26,363 | 0.132 | –20.967 | <0.001 |
| 3TC+EFV+TDF | 2.65 ± 0.75 | 2.50 ± 0.69 | –0.16 | 81,947 | 0.001 | 2.50 ± 0.70 | –0.17 | 63,640 | <0.001 | 2.56 ± 0.73 | –0.13 | 28,246 | 0.041 | 2.61 ± 0.68 | –0.11 | 19,112 | 0.406 | –20.051 | <0.001 |
*D showed median changes in blood lipid profiles from baseline to different time points. †Z showed the Wilcoxon rank-sum test used to compare the median of lipid profiles at different time points to the baseline. ‡ADF showed the data after the difference were stationary (P <0.05), which means that the data after the difference no longer have a trend or serial correlation, but is a stable random process. 3TC+EFV+TDF: Lamivudine, efavirenz, and tenofovir disoproxil fumarate; AIDS: Acquired immunodeficiency syndrome; BIC/FTC/TAF: Bictegravir, emtricitabine, and tenofovir alafenamide; BMI: Body Mass Index; HDL-C: High-density lipoprotein cholesterol; HIV: Human immunodeficiency virus; IQR: Interquartile range; LDL-C: Low-density lipoprotein cholesterol; SD: Standard deviation; TG: Triglyceride; TC: Total cholesterol.